Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkaf484 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von R C Wilson und 13 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Antimicrobial Optimisation, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Drug Monitoring, Anti-Bacterial Agents, Ambulatory Care. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Imperial College Healthcare.
Abstract (Originalsprache)
Objectives
Notwithstanding the wide uptake of outpatient antimicrobial therapy (OPAT) in the UK, there is a paucity of data on antimicrobial exposure. We aimed to assess antimicrobial pharmacokinetic–pharmacodynamics (PK–PD) for several agents in our service with a view to understanding a potential role for therapeutic drug monitoring (TDM) and precision antimicrobial therapy in this setting.
Methods
The study was a prospective, observational, pilot PK–PD study. Adult patients receiving intravenous ceftazidime, ceftriaxone, daptomycin, ertapenem, flucloxacillin or teicoplanin, or oral treatment with linezolid were enrolled. Peak and trough blood samples were obtained. Total and unbound antibacterial concentrations were measured. Clinical details, laboratory findings and UK OPAT good practice recommendation metrics were extracted from the medical record. PK–PD was interpreted according to EUCAST rationale documents and other published guidance. Doses were not adjusted except for linezolid and teicoplanin.
Results
In total, 39 patients were recruited to the study, predominantly on ceftriaxone (21/39, 54%) or ertapenem (6/39, 15%). Four patients received (10%) teicoplanin, three (8%) ceftazidime, three (8%) flucloxacillin, one (3%) linezolid and one (3%) daptomycin. The most common reason for OPAT was bacteraemia and endocarditis (6/39; 15% each). PK–PD target attainment was acceptable for all drugs and dose regimens, and all β-lactam-based treatments met conservative PK–PD targets.
Conclusions
We have demonstrated that drug monitoring is practicable in the OPAT setting of a large institution with no on-site analytical capability. Current dosage regimens result in acceptable PK–PD target attainment. Our findings provide an initial step towards supporting TDM in OPAT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Antimicrobial Optimisation, Imperial College London, London, UK.
- Pharmacy Department, Imperial College Healthcare NHS Trust, London, UK.
- National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.
- David Price Evans Infectious Diseases & Global Health Group, The University of Liverpool, Liverpool, UK.
- OPAT Service, Imperial College Healthcare NHS Trust, London, UK.
- Department of Infectious Disease, Imperial College London, Charing Cross Hospital Campus, London, UK.
ORCID-Profile: R C Wilson, M J Gilchrist
Förderung
- Imperial College Healthcare
Zitieren
APA
Wilson, R. C., Gilchrist, M. J., Cele, R., d'Arc, S., Mills, E. A., Ndhlovu, C., Balancio, B., Arkell, P., Read, L., Bayliss, M., Noel, A. R., MacGowan, A. P., Holmes, A. H., & Rawson, T. M. (2026). Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf484
Vancouver
Wilson RC, Gilchrist MJ, Cele R, d'Arc S, Mills EA, Ndhlovu C, et al. Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf484
BibTeX
@article{Wilson2026,
author = {Wilson, R C and Gilchrist, M J and Cele, R and d'Arc, S and Mills, E A and Ndhlovu, C and Balancio, B and Arkell, P and Read, L and Bayliss, M and Noel, A R and MacGowan, A P and Holmes, A H and Rawson, T M},
title = {Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkaf484}
}
EUVIMED